Navigation Links
Sequoia Pharmaceuticals Files Second IND for 2007
Date:12/7/2007

Novel Drug Enhances Pharmacokinetic Properties of Co- Administered

Therapeutics

GAITHERSBURG, Md., Dec. 7 /PRNewswire/ -- Sequoia Pharmaceuticals, Inc. announced today that it has submitted an investigational New Drug Application (IND) with the United States Food and Drug Administration to begin human clinical trials with SPI-452, a novel pharmacokinetic enhancer. SPI-452 is designed to improve the exposure of co-administered HIV medications thereby providing more efficacious, less toxic and more user-friendly drug regimens.

Sequoia's first IND was submitted for its' novel HIV protease inhibitor, SPI-256, in February 2007, and ongoing Phase I clinical trials continue to yield favorable results.

"I am very impressed with the accomplishments of the teams at Sequoia. To have discovered and developed two drug candidates within five years of founding and to submit two IND's in one year is an outstanding demonstration of the commitment and capability of the entire organization. We look forward to further progress in human trials of these two novel therapeutic agents," said Steven Skolsky, CEO of Sequoia.

About Sequoia:

Sequoia Pharmaceuticals is a private, venture capital funded company that discovers and develops revolutionary new treatments, primarily for viral diseases including HIV/AIDS and HCV-induced hepatitis with a focus on the growing problem of drug- resistant infectious diseases.


'/>"/>
SOURCE Sequoia Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... March 30, 2017 , ... Vortex Biosciences , provider ... American Association for Cancer Research (AACR) Annual Meeting 2017 (April 1–5, ... rapidly collect highly enriched populations of CTCs, undamaged by labels or reagents, for ...
(Date:3/30/2017)... , March 30, 2017  Jazz Pharmaceuticals plc (Nasdaq: ... entered into license agreements with Nippon Shinyaku, Co., Ltd. ... (cytarabine and daunorubicin liposome injection), or CPX-351, in ... terms of the agreements, Nippon Shinyaku will receive exclusive ... Japan in return for an ...
(Date:3/30/2017)... 30, 2017 Personal Genome Diagnostics Inc. (PGDx) today ... American Association for Cancer Research (AACR) Annual Meeting 2017, being ... D.C.  The company also announced that five scientists associated with ... th Annual AACR Team Science Award. ... Doug Ward , ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... organization dedicated to finding cures for inflammatory bowel diseases (IBD), and ReachMD ... to deliver exclusive content to ReachMD learners. , The partnership, which launched ...
Breaking Biology Technology:
(Date:3/2/2017)... March 2, 2017 Who risk to be ... Download the full report: https://www.reportbuyer.com/product/4313699/ WILL ... SENSOR FIELD? Fingerprint sensors using capacitive technology represent ... sensor vendor Idex forecasts an increase of 360% of ... and of the fingerprint sensor market between 2014 and ...
(Date:2/28/2017)... , Feb. 28, 2017   Acuant , a ... globally, announces significant enhancements to new and core technologies ... New products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity ... technology provides the fastest and most accurate capture software ...
(Date:2/27/2017)...   Strategic Cyber Ventures , the industry,s first ... $3.5 million investment in  Polarity , the first commercial ... DC based and is led by cybersecurity veterans ... Ron Gula , also a longtime cybersecurity veteran and ... series A round of funding. This new funding will ...
Breaking Biology News(10 mins):